All articles tagged with #glp 1 weight loss drugs
GLP-1 weight-loss drugs like Wegovy and Zepbound are reshaping healthcare economics by reducing bariatric surgeries and improving cardiovascular outcomes; a May 2026 JAMA study shows surgeries fell about 34% as GLP-1 use rose 140%, with access and coverage debates shaping potential savings, even as next-generation meds promise more dramatic weight loss.
UK MHRA Yellow Card data show roughly 200 deaths linked to GLP-1 obesity drugs (about 59 with semaglutide Ozempic/Wegovy, 120 with tirzepatide Mounjaro, 37 with liraglutide Saxenda) and over 150,000 adverse reactions. The regulator notes that reportings do not prove causation and many deaths may be due to underlying illnesses, while emphasizing GLP-1 medicines are safe for the majority of users; examples in investigations include deaths of Caroline Savage and Paula Owen.
Rising demand for high-protein foods—fueled by GLP-1 weight‑loss drugs and consumer interest—has strained whey supplies, causing shortages and higher prices; Now Foods has raised whey prices and is cutting discounts, while Glanbia and Agropur are expanding production (Glanbia in New Mexico by 2027; Agropur at several plants) in an effort to calm the gap, though relief is likely months to years away.
A small Nature Medicine trial found that adding the monoclonal antibody apitegromab to tirzepatide (a GLP-1–based obesity drug) did not change total weight loss but reduced lean mass loss to about 1.6 kg (3.5 lb), or 14.6% of total weight loss, versus 3.5 kg with tirzepatide plus placebo—a 55% greater retention of lean tissue. Most participants were women; the study was limited in size and duration, so larger, longer trials are needed to assess safety and real-world benefits. Researchers also emphasize maintaining physical activity to help preserve muscle mass during weight-loss therapy.
A Wall Street Journal piece explains that GLP-1 weight-loss medications like Ozempic and Wegovy are intended as lifelong treatments for obesity, not quick lifestyle fixes; studies show most people who stop the drugs regain the lost weight within about 1.5 years, underscoring the need for ongoing treatment and monitoring.